Showing 540 – 550 of 1157 results
-
Beam Therapeutics Inc Initiation
William Blair & Company initiated research coverage of Beam Therapeutics Inc. (BEAM $19.01), a gene-editing company focused on developing innovative, precision medicines for serious diseases using the company’s proprietary base editing technology.
-
Poseida Therapeutics Inc Initiation
William Blair & Company initiated research coverage of Poseida Therapeutics, Inc. (PSTX $12.98), a clinical-stage company focused on the development of genetically engineered T-cell therapies for the treatment of cancer and gene therapies for the treatment of rare genetic diseases.
-
Ryan DeVore
View biography for Ryan DeVore, head of private wealth management.
-
John Cimaroli
View biography for John Cimaroli, partner, wealth advisor.
-
Economics Weekly: What Will Drive Interest Rates Over the Next 75 Years?
In this Economics Weekly, Richard de Chazal runs through one such paper presented this year that offers a look back and a look forward at the real neutral rate of interest (r-star).
-
How Should We Think About the End of Quantitative Tightening
In this Economics Weekly, we discuss how quantitative tightening has played out so far and what its ending might mean for financial markets.
-
COVID19s Impact on Specialty Distribution
The COVID-19 pandemic has pressured supply chains across industries, but the net impact has varied significantly depending on the end-market.
-
Packaging Industry M&A Activity Surges Amid Strong Tailwinds
M&A activity in the packaging industry has surged during the first three quarters of 2021. The industry showed resiliency during the pandemic, with accelerating growth and stable cash flows.
-
PSG Equity Has Made a Minority Investment in SavvyMoney
William Blair served as exclusive financial advisor to PSG Equity (PSG) in connection with its minority investment in SavvyMoney, a portfolio company of Spectrum Equity.
-
Daniel N. Furhman
View biography for Daniel N. Furhman, managing director, wealth advisor.